Invivyd Inc. (IVVD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability and immune response of VYD2311 on its own, an mRNA COVID-19 vaccine on its own, and VYD2311 given together with a COVID-19 vaccine in healthy adults, the New Haven, Connecticut-based company said.
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd Q1 Earnings Call Highlights
Invivyd NASDAQ: IVVD said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to its VYD2311 development efforts.
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.14 per share a year ago.
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching
Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, but fell short of management expectations; net loss narrowed to $(52.5M) from $(170M) prior year. IVVD secured FDA Fast Track for VYD2311 and raised ~$200M in 2H 2025, providing at least two years of funding at current burn rates.
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination
Invivyd, Inc. remains a Hold rating as it advances its monoclonal antibody pipeline, notably VYD2311 as a Covid-19 vaccine alternative. VYD2311 offers broader patient coverage and intramuscular dosing, with phase 3 DECLARATION and LIBERTY trials set to begin by end of 2025; Topline data mid-2026. Company's technology shows strong variant-neutralization, and expansion into RSV and measles prevention could unlock other market opportunities.
Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Invivyd, Inc. ( IVVD ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Katie Falzone Marc Elia Timothy Lee - Chief Commercial Officer William Duke - CFO, Principal Accounting Officer & Principal Executive Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the Q3 2025 Invivyd Earnings Conference Call.
Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript
Invivyd, Inc. ( IVVD ) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention October 30, 2025 8:30 AM EDT Company Participants Katie Falzone Marc Elia Robert Allen - Chief Scientific Officer Mark Wingertzahn - Senior Vice President of Clinical Development & Medical Affairs Timothy Lee - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Thomas Shrader - BTIG, LLC, Research Division Presentation Operator Good day and thank you for standing by.
This Fidelity stock rockets over 70% on COVID-19 alternative vaccine; Time to buy?
Invivyd (NASDAQ: IVVD), a biopharmaceutical company focused on developing protection against serious viral infectious diseases, is back in the spotlight with notable share price movement.
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.4 per share a year ago.
